Introduction: Prohepcidin is the precursor of hepcidin, a liver-derived peptide involved in iron metabolism by blocking its intestinal absorption and its release by the reticuloendothelial system. Iron overload and inflammation increase hepcidin expression, whereas anemia and hypoxia suppress it. In the present study prohepcidin levels were determined in the serum of hemodialysis (HD) patients and its correlations with iron metabolism markers, C-reactive protein (CRP) and hematocrit (Hct) were assessed. Patients and Methods: Forty-sixHD patients and 22 healthy volunteers were enrolled in the study. Hct, serum prohepcidin, CRP, iron, ferritin, transferrin saturation and transferrin receptors were measured. The weekly erythropoietin dose, last-month intravenous iron dose and the patients’ demographics were recorded. Results: In comparison to the healthy volunteers, the HD patients had higher serum ferritin, transferrin receptors and CRP, lower serum iron and similar transferrin saturation and prohepcidin levels. In the patient group prohepcidin levels were negatively correlated with Hct but not with any other of the examined parameters. Multiple linear regression analysis considering age, inflammation, iron adequacy, erythropoietin dose and prohepcidin levels revealed that prohepcidin was the predominant determinant of Hct. Conclusions: Taking into account the low Hct levels in the HD patients of our study, it seems plausible that the prohepcidin levels assessed in this group are inappropriately high. These functionally high prohepcidin levels may be associated with the factors that inhibit erythropoiesis in HD patients. On the other hand, the absence of other expected correlations indicates that further studies are needed in order to definitely clarify this aspect.

Keywords:
Anemia, Hemodialysis, Hepcidin, Inflammation, Iron
1.
Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806–7810.
2.
Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K: LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147–150.
3.
Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001;98:8780–8785.
4.
Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, Sirito M, Sawadogo M, Kahn A, Vaulont S: Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002;99:4596–4601.
5.
Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D, Anderson GJ: Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 2002;123:835–844.
6.
Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811–7819.
7.
Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461–2463.
8.
Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037–1044.
9.
Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S: Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002;29:327–335.
10.
Hsu CY: Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 2002;11:337–341.
11.
Bailie GR, Johnson CA, Mason NA: Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000;35:1–12.
12.
Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469–476.
13.
Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63–72.
14.
IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37(suppl 1):S182–S238.
15.
Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W: Prohepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735–743.
16.
Malyszko J, Malyszko JS, Hryszco T, Pawlak K, Mysliwiec M: Is hepcidin a link between anemia, inflammation and liver function in hemodialysis patients? Am J Nephrol 2005;25:586–590.
17.
Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR: Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004;42:387–389.
18.
Hörl WH: Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002;13:S62–S71.
19.
Ludwiczek S, Aigner E, Theurl I, Weiss G: Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003;101:4148–4154.
20.
Tarng D-C, Huang T-P: Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients. Nephrol Dial Transplant 2002;17:1063–1069.
21.
Deira Lorenzo J, Martinn M, Sanchez S, Tabernero J: Assessment of erythropoiesis activity during hemodialysis therapy by levels and ferrokinetics measurements. Am J Kidney Dis 2001;37:550–556.
22.
Castell JV, Andus T, Kunz D, Heinrich PC: Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann NY Acad Sci 1989;557:87–99.
23.
Torti FM, Torti SV: Regulation of ferritin genes and protein. Blood 2002;99:3505–3516.
24.
Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T: Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005;105:1797–1802.
25.
Dallalio G, Law E, Means RT Jr: Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2702–2704.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.